基于DNA甲基化建模的颅脑膜瘤临床管理框架
该研究利用近2000例手术治疗的脑膜瘤样本的DNA甲基化数据和临床结局,将现有甲基化预测模型二分为四个风险组(低/高复发风险,各含放疗敏感/抵抗亚组),并与无进展生存期关联。结果显示所有风险组均从全切除获益,高危放疗敏感和低危放疗敏感组在部分切除后接受辅助放疗可改善PFS,而放疗抵抗组未获益,从而提出一个将分子模型整合入临床决策的实用框架。
要点
- 所有甲基化风险组均从全切除中获益。
- 高危放疗敏感组接受辅助放疗可改善无进展生存期。
- 低危放疗敏感组在次全切除后也可考虑放疗。
核心结论
- 识别出可从辅助放疗额外获益的甲基化定义脑膜瘤风险组,形成临床决策框架。
研究设计与样本
- 利用近2000例手术治疗的脑膜瘤队列,包含DNA甲基化谱和临床结局数据。
主要发现
- 低危放疗抵抗组(n=84,4.3%)和高危放疗抵抗组(n=356,18.2%)均未从放疗中获益,后者结局普遍较差。
关键数值与推荐
- 所有风险组均从全切除获益。
临床怎么用
- 对于高危放疗敏感脑膜瘤,术后应考虑辅助放疗。
- 低危放疗敏感患者若次全切除,可考虑辅助放疗。
- 放疗抵抗组患者应避免辅助放疗,尤其是高危抵抗组需探索其他策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. METHODS: We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. RESULTS: We first demonstrated that all risk groups benefit from gross total resection. All "high-risk, RT sensitive" tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). "Low-risk, RT sensitive cases" (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither "low-risk RT resistant" (n = 84, 4.3%) nor "high-risk RT resistant" (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. CONCLUSIONS: We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.
引用
- Landry AP, Wang JZ, Patil V, et al. A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma. Neuro Oncol. 2026. PMID: 41259653. doi:10.1093/neuonc/noaf237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。